Peanut oral immunotherapy shows promising results in adults, with significant increases in the highest tolerated dose. A study involving 18 patients demonstrated that 78% tolerated at least 1.4 g of peanut protein, while 67% of the intention-to-treat population met the primary endpoint. The median highest tolerated dose surged from 30 mg to 3000 mg, a remarkable 100-fold increase. Additionally, 56% of the primary efficacy group achieved the secondary endpoint of tolerating a cumulative dose of 4.4 g of peanut protein.
Read more from ajmc.com
